Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment

•The efficacy of axitnib is not affected by renal impairment.•Treatment outcomes including Objective response rate and Progression-free survival are were comparable among the five groups categorized according to renal function.•Among patients with an eGFR

Saved in:
Bibliographic Details
Published in:Urologic oncology 2023-11, Vol.41 (11), p.458.e9-458.e19
Main Authors: Minami, Keita, Osawa, Takahiro, Kojima, Takahiro, Hara, Tomohiko, Eto, Masatoshi, Takeuchi, Ario, Nakai, Yasutomo, Ueda, Kosuke, Ozawa, Michinobu, Uemura, Motohide, Ohba, Kojiro, Tamura, Keita, Shindo, Tetsuya, Nakagomi, Hiroshi, Takahashi, Atsushi, Anai, Satoshi, Yokomizo, Akira, Morizane, Shuichi, Kimura, Takahiro, Shimazui, Toru, Miyauchi, Yasuyuki, Mitsuzuka, Koji, Hara, Hiroaki, Yoshimura, Koji, Shiina, Hiroaki, Ito, Youichi M, Murai, Sachiyo, Nishiyama, Hiroyuki, Shinohara, Nobuo, Kitamura, Hiroshi
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Axitinib
Axitinib - therapeutic use
Carcinoma, Renal Cell - pathology
Cohort Studies
Humans
Indazoles - adverse effects
Kidney Neoplasms - pathology
Metastatic
Renal cell carcinoma
Renal impairment
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The efficacy of axitnib is not affected by renal impairment.•Treatment outcomes including Objective response rate and Progression-free survival are were comparable among the five groups categorized according to renal function.•Among patients with an eGFR
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2023.08.008